OpenURL Connection Search

Select item for more details and to access through your institution.

The Lyme disease agent Borrelia burgdorferi requires BB0690, a Dps homologue, to persist within ticks.
Published in:
Molecular Microbiology, 2007, v. 63, n. 3, p. 694, doi. 10.1111/j.1365-2958.2006.05550.x
By:
- Xin Li;
- Utpal Pal;
- Ramamoorthi, Nandhini;
- Xianzhong Liu;
- Desrosiers, Daniel C.;
- Eggers, Christian H.;
- Anderson, John F.;
- Radolf, Justin D.;
- Fikrig, Erol
Publication type:
Article
The Lyme disease agent exploits a tick protein to infect the mammalian host.
Published in:
Nature, 2005, v. 436, n. 7050, p. 573, doi. 10.1038/nature03812
By:
- Ramamoorthi, Nandhini;
- Narasimhan, Sukanya;
- Utpal Pal;
- Fukai Bao;
- Yang, Xiaofeng F.;
- Fish, Durland;
- Anguita, Juan;
- Norgard, Michael V.;
- Kantor, Fred S.;
- Anderson, John F.;
- Koski, Raymond A.;
- Fikrig, Erol
Publication type:
Article
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial.
Published in:
Arthritis & Rheumatology, 2020, v. 72, n. 9, p. 1435, doi. 10.1002/art.41275
By:
- Cohen, Stanley;
- Tuckwell, Katie;
- Katsumoto, Tamiko R.;
- Zhao, Rui;
- Galanter, Joshua;
- Lee, Chin;
- Rae, Julie;
- Toth, Balazs;
- Ramamoorthi, Nandhini;
- Hackney, Jason A.;
- Berman, Alberto;
- Damjanov, Nemanja;
- Fedkov, Dmytro;
- Jeka, Slawomir;
- Chinn, Leslie W.;
- Townsend, Michael J.;
- Morimoto, Alyssa M.;
- Genovese, Mark C.;
- Porto, Alejandro;
- Granel, Amelia
Publication type:
Article
Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses.
Published in:
Arthritis & Rheumatology, 2015, v. 67, n. 9, p. 2343, doi. 10.1002/art.39192
By:
- Rivellese, Felice;
- Suurmond, Jolien;
- Habets, Kim;
- Dorjée, Annemarie L.;
- Ramamoorthi, Nandhini;
- Townsend, Michael J.;
- de Paulis, Amato;
- Marone, Gianni;
- Huizinga, Tom W. J.;
- Pitzalis, Costantino;
- Toes, René E. M.
Publication type:
Article
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial.
Published in:
Arthritis & Rheumatology, 2021, v. 73, n. 10, p. 1835, doi. 10.1002/art.41811
By:
- Isenberg, David;
- Furie, Richard;
- Jones, Nicholas S.;
- Guibord, Pascal;
- Galanter, Joshua;
- Lee, Chin;
- McGregor, Anna;
- Toth, Balazs;
- Rae, Julie;
- Hwang, Olivia;
- Desai, Rupal;
- Lokku, Armend;
- Ramamoorthi, Nandhini;
- Hackney, Jason A.;
- Miranda, Pedro;
- de Souza, Viviane A.;
- Jaller‐Raad, Juan J.;
- Maura Fernandes, Anna;
- Garcia Salinas, Rodrigo;
- Chinn, Leslie W.
Publication type:
Article

Found: 5

The Lyme disease agent Borrelia burgdorferi requires BB0690, a Dps homologue, to persist within ticks.

The Lyme disease agent exploits a tick protein to infect the mammalian host.

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial.

Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses.

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial.